1. Home
  2. Portfolio
  3. Discourse



  1. Oshima H, Hioki K, Popivanova BK, Oguma K, Van Rooijen N, Ishikawa TO, Oshima M. Prostaglandin E(2) signaling and bacterial infection recruit tumor-promoting macrophages to mouse gastric tumors. Gastroenterology 2011; 140:596,607.e7; PMID: 21070778; DOI: 10.1053/j.gastro.2010.11.007; 10.1053/j.gastro.2010.11.007.
  2. Oshima H, Popivanova BK, Oguma K, Kong D, Ishikawa TO, Oshima M. Activation of epidermal growth factor receptor signaling by the prostaglandin E(2) receptor EP4 pathway during gastric tumorigenesis. Cancer Sci 2011; 102:713-9; PMID: 21205091; DOI: 10.1111/j.1349-7006.2011.01847.x; 10.1111/j.1349-7006.2011.01847.x.
  3. Ma X, Holt D, Kundu N, Reader J, Goloubeva O, Take Y, Fulton AM. A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE-mediated immunosuppression and inhibits breast cancer metastasis. Oncoimmunology 2013; 2:e22647; PMID: 23482441; DOI: 10.4161/onci.22647.
  4. Kundu N, Ma X, Kochel T, Goloubeva O, Staats P, Thompson K, Martin S, Reader J, Take Y, Collin P, et al. Prostaglandin E receptor EP4 is a therapeutic target in breast cancer cells with stem-like properties. Breast Cancer Res Treat 2013; PMID: 24281828; DOI: 10.1007/s10549-013-2779-4.
  5. Majumder M, Xin X, Liu L, Girish GV, Lala PK. EP4 as the common target on cancer cells and macrophages to abolish angiogenesis, lymph-angiogenesis, metastasis and SLC functions.
  6. Bhooshan N, Staats PN, Fulton AM, Feliciano JL, Edelman MJ. Prostaglandin E receptor EP4 expression, survival and pattern of recurrence in locally advanced NSCLC. Lung Cancer 2016; 101:88-91; PMID: 27794413; DOI: S0169-5002(16)30477-9 [pii].